The effect of magnesium in patients with attention deficit hyperactivity disorder

Evaluation of the efficacy of the methylphenidate in combination with magnesium and methylphenidate with placebo in patients with attention deficit hyperactivity disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160813029327N19

Enrollment

Registered

2020-09-07

Start date

2018-08-06

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: Intervention group: patients will receive 0.3 to 2 mg/kg/day methylphenidate tablet and magnesium at a dose of 125 mg/day for patients less than 35 kg and 250 mg/day for patients more

Eligibility

Sex/Gender

All

Age

8 Years to 16 Years

Inclusion criteria

Inclusion criteria: Age between 8-16 years old Diagnosis of ADHD by the pediatric psychiatrist Lack of mental retardation No history of epilepsy and seizure Intake methylphenidate tablet as the main method of drug therapy Consent of the patient and parents to participate in the research

Exclusion criteria

Exclusion criteria: Renal failure intolerance to magnesium

Design outcomes

Primary

Measure	Time frame
Scores in Conner's Parent Rating Scale questionnaire. Timepoint: Before, 4 weeks and 8 weeks after intervention. Method of measurement: Conner's Parent Rating Scale questionnaire.;Scores in ADHD Rating Scale questionnaire. Timepoint: Before, 4 weeks and 8 weeks after intervention. Method of measurement: ADHD Rating Scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Abrishami

Islamic Azad University

r_abrishami@iaups.ac.ir+98 21 2264 0051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026